Dobixin 2 mg/ml (IV Infusion)
10 mg vial: ৳ 275.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Doxorubicin hydrochloride |
| Company | Drug international ltd |
Indications
- Component of multiagent adjuvant chemotherapy for women with axillary lymph node involvement following resection of primary breast cancer
- Treatment of acute lymphoblastic leukemia
- Treatment of acute myeloblastic leukemia
- Treatment of Hodgkin lymphoma
- Treatment of Non-Hodgkin lymphoma
- Treatment of metastatic breast cancer
- Treatment of metastatic Wilms' tumor
- Treatment of metastatic neuroblastoma
- Treatment of metastatic soft tissue sarcoma
- Treatment of metastatic bone sarcomas
- Treatment of metastatic ovarian carcinoma
- Treatment of metastatic transitional cell bladder carcinoma
- Treatment of metastatic thyroid carcinoma
- Treatment of metastatic gastric carcinoma
- Treatment of metastatic bronchogenic carcinoma
Pharmacology
- Cytotoxic anthracycline topoisomerase II inhibitor
- Nucleotide base intercalation
- Cell membrane lipid binding
- Inhibition of nucleotide replication
- Formation of DNA-cleavable complexes
- Cytocidal activity
Dosage & Administration
- Single agent dosage: 60 to 75 mg/m2 given intravenously every 21 days
- Combination therapy dosage: 40 to 75 mg/m2 given intravenously every 21 to 28 days
- Administration through central intravenous line or secure peripheral venous line
- Intravenous injection over 3 to 10 minutes
- Intravenous infusion only through a central catheter
- Management of Suspected Extravasation protocol
- Incompatibility with other drugs
Interaction
- Major substrate of cytochrome P450 CYP3A4 and CYP2D6, and P-glycoprotein (P-gp)
- Avoid concurrent use with inhibitors and inducers of CYP3A4, CYP2D6, or P-gp
- Increased risk of cardiac dysfunction with Trastuzumab
- Interaction with Paclitaxel
Contraindications
- Severe myocardial insufficiency
- Recent myocardial infarction
- Severe persistent drug-induced myelosuppression
- Severe hepatic impairment
- Severe hypersensitivity reaction
Side Effects
- Alopecia
- Nausea and vomiting
- Cardiomyopathy and arrhythmias
- Secondary malignancies
- Extravasation and tissue necrosis
- Severe myelosuppression
- Tumor lysis syndrome
- Radiation sensitization and recall
Pregnancy & Lactation
- Category D pregnancy rating
- Potential fetal harm
- Use of effective contraception during and after treatment
- Presence in human milk
Use in Special Populations
- Pediatric use risk for late cardiovascular dysfunction
- Periodic cardiovascular monitoring recommended for pediatric patients
- No overall geriatric differences in safety and effectiveness
- Reduced clearance in hepatic impaired patients
Overdose Effects
- Extension of pharmacological action
- Fatal at single doses of 250 mg and 500 mg
- Acute myocardial degeneration
- Severe myelosuppression
- Delayed cardiac failure
Therapeutic Class
- Cytotoxic Chemotherapy
Reconstitution
- Preparation for Administration with specific injection solutions
- Protection from light during preparation and infusion
- Precautions during Handling to minimize dermal exposure
Storage Conditions
- Temperature range of 2°C to 8°C
- Protection from light
- Avoid freezing
- Keep out of the reach of children